Premium
Harnessing Dendritic Cells to Generate Cancer Vaccines
Author(s) -
Palucka Karolina,
Ueno Hideki,
Fay Joseph,
Banchereau Jacques
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.05000.x
Subject(s) - immunotherapy , cd8 , dendritic cell , cancer immunotherapy , immunology , active immunotherapy , immune system , antigen , cytotoxic t cell , effector , adoptive cell transfer , immunity , biology , t cell , cancer research , medicine , in vitro , biochemistry
Passive immunotherapy of cancer (i.e., transfer of T cells or antibodies) can lead to some objective clinical responses, thus demonstrating that the immune system can reject tumors. However, passive immunotherapy is not expected to yield memory T cells that might control tumor outgrowth. Active immunotherapy with dendritic cell (DC) vaccines has the potential to induce tumor‐specific effector and memory T cells. Clinical trials testing first‐generation DC vaccines pulsed with tumor antigens provided a proof‐of‐principle that therapeutic immunity can be elicited. Newer generation DC vaccines are built on the increased knowledge of the DC system, including the existence of distinct DC subsets and their plasticity all leading to the generation of distinct types of immunity. Rather than the quantity of IFN‐γ‐secreting CD8 + T cells, we should aim at generating high‐quality, high‐avidity, polyfunctional effector CD8 + T cells able to reject tumors and long‐lived memory CD8 + T cells able to prevent relapse.